By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D.
Faculty Peer Reviewed
Recent publications have described a potential drug interaction between clopidogrel (Plavix®) and proton pump inhibitors (PPIs). Several retrospective …
Category: Pharmacology
Clinical Correlations
Antimicrobial Therapy Geared at Pseudomonas aeruginosa for Bronchiectasis
April 7, 2010
Diana Hubulashvili, Pharm.D.
Edited by Tania Ahuja, Pharm.D., BCPS
Read More
When Clopidogrel Fails…
March 10, 2010
Marisa Mizus
Faculty peer reviewed
Clopidogrel (Plavix) has been the standard of care for patients with coronary artery disease following percutaneous coronary intervention (PCI) for the past decade. Although it …
Zolpidem and Uncontrollable Nocturnal Eating Binges
February 24, 2010
John Cruz
Faculty peer reviewed
A number of studies have shown that zolpidem (Ambien), the most commonly prescribed sleep-inducing medication on the market, can produce uncontrollable nocturnal eating …
Breaking News: FDA issues new warning for Exenatide (Byetta®)
November 5, 2009
Kanika Ballani, Pharm.D.
Diana Hubulasvili, Pharm.D.
Developed by Amylin Pharmaceuticals, Exenatide (Byetta®) is an incretin mimetic that is used as an adjunctive therapy with metformin, a sulfonylurea or a thiazolidinedione to improve glycemic …
Clinical Questions: How do you dose argatroban?
April 16, 2009
Frederick Gandolfo, MD
Case: An 85 year-old woman admitted to the hospital with pneumonia and after a prolonged hospital course developed heparin-induced thrombocytopenia (HIT). She is …
Grand Rounds: “Activated Protein C, Translational Research models of Sepsis and Stroke”
January 28, 2009
Commentary by Adi Diab MD, PGY-3
This past week on January 21th, Medical Grand Rounds was given by guest speaker Dr. John Griffin who shared his knowledge of the role of Activate Protein …
Breaking News: Revenge of the Gila Monster?
August 20, 2008
Commentary by Rachana Jani MD, PGY-2
As recently reported in ShortCuts, Byetta recently made headlines after the suggestion of a mortality benefit for patients taking the drug in a small subset of the Accord study. So is this the new golden drug …